Obese rhesus monkeys lost an average of 11% of their body weight after four weeks of treatment with an experimental drug that selectively destroys the blood supply of fat tissue.
Biosearch Technologies Inc.’s Stellaris Fish Probes are an RNA visualization method that allows detection, localization, and quantification of individual mRNA molecules at the sub-cellular level in fixed samples.
Constructed in pure grade polystyrene, the Krystal 2000 plate from Porvair Sciences is designed for luminescence applications that require photometric accuracy and repeatability.
TAP Biosystems’ Cell-IQ software comes with two plate positions that allow cells to be to be maintained for days or weeks, side by side in normoxia. Researchers can train the system to recognize experimental characteristics including cell attachment phases, scratch wound proliferation and migration assays.
Integrated DNA Technologies now offers its customers the ability to order RxnReady oligonucleotides. Users can specify the premixing of 2 – 6 standard desalted DNA oligos, in a single tube, according to the individual specifications provided.
Thermo Fisher Scientific Inc. has introduced its PikoReal Real-Time PCR Systems, which complete its molecular biology workflow. Available in 24- and 96-well formats, the PikoReal offers performance in a small bench-top footprint.
MPI Research has announced that David Serota, PhD, DABT, senior vice president of drug safety development and senior principal study director, will serve as the 2012 American College of Toxicology president.
Merck & Co. said it has launched the long-acting birth control implant Nexplanon in the United States. Nexplanon has been approved by the Food and Drug Administration for the prevention of pregnancy in women for up to three years.
Genentech announced that the U.S. Food and Drug Administration has accepted and filed the company’s New Drug Application for vismodegib for the treatment of adults with advanced basal cell carcinoma for whom surgery is considered inappropriate.
Sinovac Biotech Ltd. announced positive top-line results from its Phase 2 clinical trial for its inactivated vaccine against human enterovirus 71, which causes hand, foot and mouth disease.
Merck & Co. plans in the next two years to seek U.S. approval for eight new medicines and has other promising drugs in late-stage testing, including drugs for chronic insomnia, hardening of the arteries, osteoporosis, and reversal of anesthesia.
Biotech drugmaker Affymax Inc. reported a smaller third-quarter loss and said it settled litigation with Johnson & Johnson over its top drug candidate, the anemia treatment peginesatide.
Medivation Inc. reported a bigger third-quarter loss than it did a year earlier as it continued to develop treatments for prostate cancer and Alzheimer's disease.
A group of California pharmacies are accusing Pfizer Inc. and a generic drug maker of conspiring to keep the price of cholesterol-fighting Lipitor artificially high.
The Georgia Institute of Technology will receive funding through Grand Challenges Explorations, an initiative created by the Bill and Melinda Gates Foundation that enables researchers to test ideas that address health and development challenges.